BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
Issued Date
2022-10-24
Resource Type
eISSN
21697574
Scopus ID
2-s2.0-85149132434
Journal Title
Plastic and Reconstructive Surgery - Global Open
Volume
10
Issue
10
Rights Holder(s)
SCOPUS
Bibliographic Citation
Plastic and Reconstructive Surgery - Global Open Vol.10 No.10 (2022) , E4605
Suggested Citation
Meevassana J., Anothaisatapon K., Subbalekha S., Kamolratanakul S., Siritientong T., Ruangritchankul K., Pungrasami P., Hamill K.J., Angsapatt A., Kitkumthorn N. BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population. Plastic and Reconstructive Surgery - Global Open Vol.10 No.10 (2022) , E4605. doi:10.1097/GOX.0000000000004605 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85443
Title
BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
Other Contributor(s)
Abstract
Background: The BRAF V600E mutation in the Thai population has been identified in a considerable percentage of people with cutaneous melanoma. The objectives of this study were to determine the prevalence of this mutation in cutaneous melanomas, conduct a clinicopathological association analysis with the BRAF V600E mutation, and develop a treatment strategy for patients with this mutation that would take advantage of the medications currently available to treat them. Methods: Anti-BRAF V600E (clone VE1) immunohistochemistry was performed on 50 pathological samples of cutaneous melanoma after excluding the samples with a low amount of pathologic tissue, a lack of clinical data‚ and poor follow-up. BRAF V600E expression DNA sequencing was performed to confirm the results of several cases. Results: Anti-BRAF V600E antibody positivity was noted in 56% (28/50) of cutaneous melanoma cases. DNA sequencing results were consistent with immunohistochemistry results. In cutaneous melanoma, the BRAF V600E mutation was significantly associated with adverse prognosis of patients, including reduced overall survival and disease-free survival. Conclusions: An increased prevalence of the BRAF V600E mutation was determined in a collection of cutaneous melanomas in the Thai population, implying that BRAF-targeted therapy may be a promising strategy for patients with BRAF-mutated cutaneous melanoma. This study revealed an association between the clinicopathological aspects of cutaneous melanoma and overall survival, disease-free survival, and overall mortality. A treatment with anti-BRAF-targeted therapy, which incorporates the already available medications‚ is being researched and developed.